# Simvastatin in Overcoming Chemotherapy Resistance in Patients With Relapsed or Refractory Multiple Myeloma

> **NCT02971410** · EARLY_PHASE1 · WITHDRAWN · sponsor: **Wake Forest University Health Sciences**

## Conditions studied

- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma

## Interventions

- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Quality-of-Life Assessment
- **DRUG:** Simvastatin

## Key facts

- **NCT ID:** NCT02971410
- **Lead sponsor:** Wake Forest University Health Sciences
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2017-04
- **Primary completion:** 2021-11
- **Final completion:** 2021-11
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** PI no longer interested in pursuing study.
- **Last updated:** 2018-07-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02971410

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02971410, "Simvastatin in Overcoming Chemotherapy Resistance in Patients With Relapsed or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02971410. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*